Evidence map›Paper›PMID 42363830›Full record

ArticleAntimicrobial agents and chemotherapy2026

Pyocyanin produced by

M G J de Vos, V Jansen, O El Bouhlali, A A Vlasblom, L E Zandbergen, I van der Windt, C I Sey, J Kool, R Nijland, A de Jong and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

M G J de VosGroningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, the Netherlands.ORCID 0000-0003-0601-908X
V JansenDepartment of Physiology, Amsterdam UMC, Amsterdam, the Netherlands.
O El BouhlaliLaboratory of Genetics, Wageningen University, Wageningen, the Netherlands.
A A VlasblomUniversity of Utrecht, Population Health, Utrecht, the Netherlands.ORCID 0000-0002-9186-9515
L E ZandbergenGroningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, the Netherlands.
I van der WindtGroningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, the Netherlands.
C I SeyGroningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, the Netherlands.
J KoolField Technology Innovations, Wageningen Research, Wageningen, the Netherlands.
R NijlandMarine Animal Ecology, Wageningen University, Wageningen, the Netherlands.ORCID 0000-0003-0049-3768
A de JongGroningen Biomolecular Sciences and Biotechnology, University of Groningen, Groningen, the Netherlands.
O P KuipersGroningen Biomolecular Sciences and Biotechnology, University of Groningen, Groningen, the Netherlands.ORCID 0000-0001-5596-7735
S DunnSchool of Infection, University of Birmingham, Birmingham, United Kingdom.
A McNallySchool of Infection, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0002-3099-630X
J A G M de VisserLaboratory of Genetics, Wageningen University, Wageningen, the Netherlands.ORCID 0000-0002-5098-6686

Funding

Adaptive Life Program - GELIFESLOreal Unesco LNVH NIAS-KNAW For Women in Science FellowshipNWO VENI Fellowship 863.14.015
6 · The paper itself

Abstract

Polymicrobial infections are small communities of multiple interacting bacterial species. Interactions among constituent species may modify the growth of community members in the presence of antibiotics, for example, via degradation of the antibiotic, the induction of specific resistance mechanisms, or increased mutation supply rates. However, for most polymicrobial infections, the nature of such interactions is opaque, while they may affect both treatment efficacy and the evolution of antibiotic resistance. Here, we describe that past interaction of enterococci with

Indexed as

Anti-Bacterial AgentsEnterococcusPseudomonas aeruginosaPyocyanineDrug Resistance, BacterialMicrobial Sensitivity TestsNalidixic AcidRifampinAnti-Bacterial AgentsNalidixic AcidPyocyanineRifampinantibiotic resistanceeffluxevolvabilityinfectious diseasesmicrobial ecologysecondary metabolites

Identifiers

PMID42363830
PMCPMC13436219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.